低剂量他莫昔芬预防乳腺非浸润性肿瘤复发的随机安慰剂对照试验:TAM-01 研究 10 年随访
TAM-01 是一项 III 期随机安慰剂对照试验,500 例乳腺上皮内瘤变女性术后接受低剂量他莫昔芬 5 mg 每日一次或安慰剂治疗 3 年。中位随访 9.7 年显示,他莫昔芬组发生 25 例乳腺癌事件,安慰剂组 41 例(HR 0.58,95%CI 0.35-0.95,P=0.03),对侧乳腺癌事件分别为 6 例和 16 例(HR 0.36,95%CI 0.14-0.92,P=0.025),未报告严重不良事件组间差异。
要点
- 中位随访 9.7 年,他莫昔芬组 25 例 vs 安慰剂组 41 例乳腺癌事件(HR 0.58,95%CI 0.35-0.95,P=0.03)。
- 对侧乳腺癌他莫昔芬组 6 例 vs 安慰剂组 16 例(HR 0.36,95%CI 0.14-0.92,P=0.025)。
- DCIS 队列他莫昔芬组复发风险降低 50%(HR 0.50,95%CI 0.28-0.91,P=0.02)。
核心结论
- 他莫昔芬 5 mg 每日一次治疗 3 年可显著预防非浸润性乳腺癌在停药后 7 年时的复发,且无长期不良事件。
研究设计与样本
- III 期随机安慰剂对照试验 TAM-01,随机分配 500 例乳腺上皮内瘤变女性(20% 非典型导管增生、11% 小叶原位癌、69% 导管原位癌)至低剂量他莫昔芬或安慰剂,术后接受或不接受放疗。
- 低剂量他莫昔芬为 5 mg 每日一次,治疗 3 年。
- 主要终点为浸润性乳腺癌或导管原位癌的发生率。
- 中位随访 9.7 年(IQR 8.3-10.9 年)。
主要发现
- 共诊断 66 例乳腺癌(15 例原位、51 例浸润性):他莫昔芬组 25 例 vs 安慰剂组 41 例;年发生率每 1000 人年他莫昔芬组 11.3 vs 安慰剂组 19.5(HR 0.58,95%CI 0.35-0.95,log-rank P=0.03)。
- 大多数复发为浸润性(77%)且为同侧(59%)。
- 对侧乳腺癌发生率他莫昔芬组 6 例 vs 安慰剂组 16 例(HR 0.36,95%CI 0.14-0.92,P=0.025)。
- DCIS 队列他莫昔芬组复发风险降低 50%(HR 0.50,95%CI 0.28-0.91,P=0.02),该队列占总体人群 70%。
- 预防一例乳腺事件需治疗人数他莫昔芬组 5 年为 22 例、10 年为 14 例;延长随访期间未报告严重不良事件发生率的组间差异。
临床怎么用
- 原文结论为:他莫昔芬 5 mg 每日一次治疗 3 年显著预防非浸润性乳腺癌在停药后 7 年时的复发,且无长期不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo. Here, we present the 10-year results. METHODS: We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without irradiation. The primary end point was the incidence of invasive breast cancer or DCIS. RESULTS: The TAM-01 population included 500 women (20% atypical ductal hyperplasia, 11% LCIS, and 69% DCIS). The mean (±SD) age at the start of treatment was 54 ± 9 years, and 58% of participants were postmenopausal. After a median follow-up of 9.7 years (IQR, 8.3-10.9 years), 66 breast cancers (15 in situ; 51 invasive) were diagnosed: 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years, 11.3 with tamoxifen v 19.5 with placebo; hazard ratio [HR], 0.58; 95% CI, 0.35 to 0.95; log-rank P = .03). Most recurrences were invasive (77%) and ipsilateral (59%). Regarding contralateral breast cancer incidence, there were six events in the tamoxifen arm and 16 in the placebo arm (HR, 0.36; 95% CI, 0.14 to 0.92; P = .025). The number needed to be treated to prevent one case of breast event with tamoxifen therapy was 22 in 5 years and 14 in 10 years. The benefit was seen across all patient subgroups. There was a significant 50% reduction of recurrence with tamoxifen in the DCIS cohort, which represents 70% of the overall population (HR, 0.50; 95% CI, 0.28 to 0.91; P = .02). No between-group difference in the incidence of serious adverse events was reported during the prolonged follow-up period. CONCLUSION: Tamoxifen 5 mg once daily for 3 years significantly prevents recurrence from noninvasive breast cancer after 7 years from treatment cessation without long-term adverse events.
引用
- Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin Oncol. 2023. PMID: 36917758. doi:10.1200/JCO.22.02900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。